The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | INFINITY: neoadjuvant or definitive tremelimumab with durvalumab in MSI GAC/GEJAC
Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, explores the Phase II INFINITY trial (NCT04817826) of tremelimumab plus durvalumab as neoadjuvant or definitive treatment in MSI high, resectable gastric and gastroesophageal junction adenocarcinoma (GAC/GEJAC). Non-operative management was found to be feasible in this cohort of patients and the treatment additionally demonstrated safety with manageable adverse events and maintained quality of life. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi-Sankyo; Ipsen; Johnson&Johnson; Merck Serono; MSD Oncology; Pierre Fabre; Rottapharm Biotech; Seagen; SERVIER; Takeda
Consulting or Advisory Role – Amgen; Bayer; GlaxoSmithKline; Janssen; Merck Serono; MSD Oncology; Rottapharm Biotech; SERVIER; Takeda
Research Funding – Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst)
Travel, Accommodations, Expenses – Merck Serono; Pierre Fabre
